Improving the radical cure of vivax malaria (IMPROV): A study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens

• Main Authors: Tesfay Abreha, Bereket Alemayehu, Ashenafi Assefa, Ghulam Rahim Awab, J. Kevin Baird, Beay Bezabih, Phaik Yeong Cheah, Nicholas P. Day, Angela Devine, Mehul Dorda, Arjen M. Dondorp, Samuel Girma, Tran Tinh Hien, Daddi Jima, Moges Kassa, Amha Kebende, Naw Htee Khu, Toby Leslie, Benedikt Ley, Yoel Lubell, Ismail Mayan, Zenebe Meaku, Ayodhia P. Pasaribu, Nguyen Hoan Phu, Ric N. Price, Julie A. Simpson, Hiwot Solomon, Inge Sutanto, Yehualahet Tadesse, Bob Taylor, Ngo Viet Thanh, Kamala Thriemer, Lorenz von Seidlein, Nicholas White, Adugna Woyessa, Prayoon Yuentrakul, Rohullah Zekria
• Other Authors: Columbia University Mailman School of Public Health
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/36220
• Institution: Mahidol University

© 2015 The IMPROV Study Group. Background: Plasmodium vivax malaria is a major cause of morbidity and recognised as an important contributor to mortality in some endemic areas. The current recommended treatment regimen for the radical cure of P. vivax includes a schizontocidal antimalarial, usually...